Aduro Biotech Financials

Aduro Biotech Stock Summary

Aduro Biotech competes with Nippon Steel, Bill, ZK International, Corning Incorporated, and Kaltura. Aduro Biotech, Inc., an immunotherapy company, focuses on the discovery, development, and commercialization of therapies to harness the bodys natural immune system for the treatment of patients with challenging diseases. Aduro Biotech, Inc. was founded in 2000 and is headquartered in Berkeley, California. Aduro Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 69 people.

Aduro Biotech Key Financial Ratios

Generally speaking, Aduro Biotech's financial ratios allow both analysts and investors to convert raw data from Aduro Biotech's financial statements into concise, actionable information that can be used to evaluate the performance of Aduro Biotech over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Aduro Biotech reports annually and quarterly.

Aduro Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Aduro Biotech's current stock value. Our valuation model uses many indicators to compare Aduro Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Aduro Biotech competition to find correlations between indicators driving Aduro Biotech's intrinsic value. More Info.Aduro Biotech is number one stock in return on equity category among related companies. It is number one stock in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Aduro Biotech by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Aduro Biotech's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Aduro Biotech's earnings, one of the primary drivers of an investment's value.

Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

If you are still planning to invest in Aduro Biotech check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aduro Biotech's history and understand the potential risks before investing.